RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 17 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 17

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Luhe Hospital首都医科大学附属北京潞河医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  3. Study siteFirst Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第一医院HarbinHospital page
  4. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  5. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  6. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  7. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  8. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  9. Study siteLanzhou University Second Hospital兰州大学第二医院LanzhouHospital page
  10. Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
  11. Study siteSecond Hospital of Tianjin Medical University天津医科大学第二医院TianjinHospital page
  12. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  13. Study siteShaanxi Provincial People's Hospital陕西省人民医院Xi'anHospital page
  14. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  15. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  16. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page
  17. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07521007, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.

    Exclusion criterion 1

    PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.

    Exclusion criterion 7

  3. Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

    Inclusion criterion 10

    Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.

    Exclusion criterion 24

    Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.

    Exclusion criterion 25

  4. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).

    Exclusion criterion 17

    A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).

    Exclusion criterion 28

  5. Female participants must be non-pregnant and non-lactating

    Inclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07521007, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  • Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  • Participants must satisfy either of the following criteria:
  • Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
  • A history of Type 2 diabetes requiring treatment with medication,
  • Aged > 55 years (women) or > 50 years (men),
  • 2 or more of the following atherosclerosis risk factors:
  • Current cigarette smoker
  • Hypertension
  • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
  • Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
  • Female participants must be non-pregnant and non-lactating
  • Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  • Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  • Previously received YN001.
  • Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  • Contraindication for CCTA
  • 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  • Acute MI that occurred within 4 weeks prior to randomization.
  • PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  • Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  • Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  • Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  • New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  • Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  • History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  • History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  • Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  • Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  • Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  • Presence of any type of autoimmune disease.
  • Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  • Life expectancy is less than 1 year.
  • Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  • Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  • LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  • Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  • Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  • Untreated or inadequately treated hypothyroidism.
  • Poorly controlled Type 2 diabetes mellitus.
  • A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  • Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Quoted from ClinicalTrials.gov, NCT07521007, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07521007, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07521007